Showing results (331-340 of 554) with videos related to
Sort By:
Pageof 56
Developmental Cell|May 8, 2019
YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor CellsShannon M White, Maria Laura Avantaggiati, Ivan Nemazanyy, et al.Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1996
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimeraE G Trehu, J W Mier, J S Dubois, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaM J Hawkins, M B Atkins, J P Dutcher, et al.Journal for Immunotherapy of Cancer|December 19, 2019
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infectionNeil J Shah, Ghassan Al-Shbool, Matthew Blackburn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II StudyMichael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.British Journal of Cancer|January 17, 2013
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenograftsX Wang, L Zhang, A O'Neill, et al.Cancer|June 11, 2015
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinomaM Dror Michaelson, Rana R McKay, Lillian Werner, et al.Cancer|September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyMichael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.Pageof 56